Document is current
Any future updates will be listed below
-
Authors
Barden, Markus https://orcid.org/0000-0002-4923-2254
Elsenbroich, Patrick Ronan https://orcid.org/0009-0006-4466-3895
Haas, Vivian
Ertelt, Moritz
Pervan, Philip
Velas, Lukas
Gergely, Bence https://orcid.org/0000-0001-9005-6910
Szöőr, Árpád
Harrer, Dennis Christoph
Bezler, Valerie
Holzinger, Astrid
Friis, Rasmus Ulslev Wegener
Vereb, Gyorgy
Schütz, Gerhard J
Schoeder, Clara T
Hombach, Andreas A https://orcid.org/0000-0001-9328-8442
Abken, Hinrich
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04430595 at ClinicalTrials.govnct01935843 at ClinicalTrials.govDocuments that mention this clinical trial
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function
https://doi.org/10.1136/jitc-2024-010208
nct03198052 at ClinicalTrials.govDocuments that mention this clinical trial
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function
https://doi.org/10.1136/jitc-2024-010208
Mechanistic data-informed multiscale quantitative systems pharmacology modeling framework enables the clinical translation and efficacy assessment of CAR-T therapy in solid tumors
https://doi.org/10.1136/jitc-2025-012331
nct04511871 at ClinicalTrials.govDocuments that mention this clinical trial
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function
https://doi.org/10.1136/jitc-2024-010208
nct00902044 at ClinicalTrials.govDocuments that mention this clinical trial
Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies
https://doi.org/10.1136/jitc-2025-014286
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function
https://doi.org/10.1136/jitc-2024-010208
nct02442297 at ClinicalTrials.govDocuments that mention this clinical trial
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function
https://doi.org/10.1136/jitc-2024-010208
nct03696030 at ClinicalTrials.govDocuments that mention this clinical trial
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function
https://doi.org/10.1136/jitc-2024-010208
Advances in the management of glioblastoma
https://doi.org/10.1136/jnnp-2020-325334
nct03500991 at ClinicalTrials.govDocuments that mention this clinical trial
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function
https://doi.org/10.1136/jitc-2024-010208
Documents that mention this clinical trial
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function
https://doi.org/10.1136/jitc-2024-010208
Locoregional delivery of CAR T cells in high-grade gliomas: a systematic analysis of safety, efficacy, and emerging biomarkers of response
https://doi.org/10.1136/jitc-2025-014450
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors
https://doi.org/10.1136/jitc-2021-004450
- License Information
